Galectin Therapeutics Ownership | Who Owns Galectin Therapeutics?

Galectin Therapeutics Ownership Summary

Galectin Therapeutics is owned by 15.51% institutional investors, 30.96% insiders, and 53.54% retail investors. Vanguard group is the largest institutional shareholder, holding 3.41% of GALT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.00% of its assets in Galectin Therapeutics shares.

GALT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Galectin Therapeutics	15.51%	30.96%	53.54%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vanguard group	2.12M	3.41%	$4.78M
Blackrock	1.56M	2.52%	$3.53M
Advisor group	1.13M	1.82%	$2.54M
Geode capital management	841.73K	1.36%	$1.90M
Commonwealth equity services	483.35K	0.78%	$1.09M
Wealthspire advisors	398.37K	0.64%	$900.33K
Geneos wealth management	393.73K	0.64%	$889.82K
State street	229.62K	0.37%	$518.93K
Morgan stanley	227.22K	0.37%	$513.51K
Atria wealth solutions	213.80K	0.34%	$483.19K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Solutions 4 wealth	36.09K	0.18%	$81.55K
Cutter & co brokerage	115.49K	0.06%	$261.00K
Retirement guys formula	41.16K	0.04%	$93.02K
Geneos wealth management	393.73K	0.04%	$889.82K
Vivaldi capital management lp	24.03K	0.02%	$54.31K
Wealthspire advisors	398.37K	0.01%	$900.33K
Beacon capital management	23.91K	0.01%	$54.02K
Traynor capital management	42.87K	0.01%	$96.89K
Advisor group	1.13M	0.01%	$2.54M
Atria wealth solutions	213.80K	0.01%	$483.19K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	1.56M	0.00%	851.14K
Commonwealth equity services	483.35K	0.00%	367.61K
Geode capital management	841.73K	0.00%	274.56K
Vanguard group	2.12M	0.00%	136.18K
State street	229.62K	-	68.17K

Top Sellers

Holder	Shares	% Assets	Change
Susquehanna group, llp	202.34K	0.00%	-157.52K
Advisor group	1.13M	0.01%	-138.85K
Qube research	-	-	-69.05K
Jane street group	-	-	-36.78K
Creative planning	-	-	-24.21K

New Positions

Holder	Shares	% Assets	Change	Value
Man group	65.70K	0.00%	65.70K	$148.48K
New york state common retirement fund	45.50K	0.00%	45.50K	$103.00K
Nuveen asset management	27.62K	-	27.62K	$62.43K
Goldman sachs group	22.56K	-	22.56K	$50.99K
Rhumbline advisers	19.27K	-	19.27K	$43.56K

Sold Out

Holder	Change
Group one trading	-542.00
Meeder asset management	-3.82K
Corecap advisors	-7.70K
Wolverine trading	-10.90K
Y-intercept (hong kong)	-11.14K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	87	14.47%	9,657,327	1.46%	15	6.57%	39	-11.36%	17	112.50%
Jun 30, 2024	76	22.58%	9,518,560	24.93%	15	9.58%	44	100.00%	8	-20.00%
Mar 31, 2024	62	-8.82%	7,618,819	7.06%	12	8.91%	22	22.22%	10	-33.33%
Dec 31, 2023	68	13.33%	7,116,188	-20.56%	11	5.27%	18	20.00%	15	66.67%
Sep 30, 2023	60	-1.64%	8,957,559	24.81%	15	10.33%	15	36.36%	9	-35.71%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	1.25M	2.00%	-
Vanguard Institutional Extnd Mkt Idx Tr	670.16K	1.08%	-
iShares Russell 2000 ETF	400.54K	0.64%	-840.00
Fidelity Extended Market Index	285.36K	0.46%	18.40K
Fidelity Small Cap Index	194.58K	0.31%	-4.27K
iShares Russell 2000 Growth ETF	108.37K	0.17%	-
Vanguard Russell 2000 ETF	92.75K	0.15%	-578.00
BlackRock Extended Equity Market K	92.01K	0.15%	-39.00
Fidelity Total Market Index	81.96K	0.13%	-201.00
iShares Russell 2000 Value ETF	75.98K	0.12%	98.00

Recent Insider Transactions

Date	Name	Role	Activity	Value
Oct 23, 2024	ELDRED KARY	-	Buy	$1.30K
Oct 17, 2024	FREEMAN KEVIN D	-	Buy	$3.43K
Oct 16, 2024	FREEMAN KEVIN D	-	Buy	$13.50K
Oct 16, 2024	FREEMAN KEVIN D	-	Buy	$13.50K
Aug 23, 2024	Zordani Richard A. Jr.	-	Buy	$2.30K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	4	-
2024 Q3	4	-
2024 Q2	4	2
2024 Q1	2	-
2023 Q4	-	-

GALT Ownership FAQ

Who Owns Galectin Therapeutics?

Galectin Therapeutics shareholders are primarily institutional investors at 15.51%, followed by 30.96% insiders and 53.53% retail investors. The average institutional ownership in Galectin Therapeutics's industry, Biotech Stocks , is 47.04%, which Galectin Therapeutics falls below.

Who owns the most shares of Galectin Therapeutics?

Galectin Therapeutics’s largest shareholders are Vanguard group (2.12M shares, 3.41%), Blackrock (1.56M shares, 2.52%), and Advisor group (1.13M shares, 1.82%). Together, they hold 7.75% of Galectin Therapeutics’s total shares outstanding.

Does Blackrock own Galectin Therapeutics?

Yes, BlackRock owns 2.52% of Galectin Therapeutics, totaling 1.56M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.53M$. In the last quarter, BlackRock increased its holdings by 851.14K shares, a 119.44% change.

Who is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested?

Solutions 4 wealth is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.18% of its assets in 36.08K Galectin Therapeutics shares, valued at 81.55K$.

Who is the top mutual fund holder of Galectin Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Galectin Therapeutics shares, with 2.00% of its total shares outstanding invested in 1.25M Galectin Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools